Literature DB >> 21253387

Genomic and genetic alterations influence the progression of gastric cancer.

Stefania Nobili1, Lorenzo Bruno, Ida Landini, Cristina Napoli, Paolo Bechi, Francesco Tonelli, Carlos A Rubio, Enrico Mini, Gabriella Nesi.   

Abstract

Gastric cancer is one of the leading causes of cancer-related deaths worldwide, although the incidence has gradually decreased in many Western countries. Two main gastric cancer histotypes, intestinal and diffuse, are recognised. Although most of the described genetic alterations have been observed in both types, different genetic pathways have been hypothesized. Genetic and epigenetic events, including 1q loss of heterozygosity (LOH), microsatellite instability and hypermethylation, have mostly been reported in intestinal-type gastric carcinoma and its precursor lesions, whereas 17p LOH, mutation or loss of E-cadherin are more often implicated in the development of diffuse-type gastric cancer. In this review, we summarize the sometimes contradictory findings regarding those markers which influence the progression of gastric adenocarcinoma.

Entities:  

Keywords:  Gastric cancer; Gene alterations; Molecular pathology; Prognosis

Mesh:

Year:  2011        PMID: 21253387      PMCID: PMC3022288          DOI: 10.3748/wjg.v17.i3.290

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  117 in total

1.  RUNX3 expression correlates with chief cell differentiation in human gastric cancers.

Authors:  N Ogasawara; T Tsukamoto; T Mizoshita; K-I Inada; H Ban; S Kondo; S Takasu; T Ushijima; K Ito; Y Ito; M Ichinose; T Ogawa; T Joh; M Tatematsu
Journal:  Histol Histopathol       Date:  2009-01       Impact factor: 2.303

Review 2.  Cytogenetic and molecular aspects of gastric cancer: clinical implications.

Authors:  Anna D Panani
Journal:  Cancer Lett       Date:  2008-04-01       Impact factor: 8.679

3.  Co-expression of keratinocyte growth factor and K-sam is an independent prognostic factor in gastric carcinoma.

Authors:  Takahiro Toyokawa; Masakazu Yashiro; Kosei Hirakawa
Journal:  Oncol Rep       Date:  2009-04       Impact factor: 3.906

4.  Methylation of the calcium channel-related gene, CACNA2D3, is frequent and a poor prognostic factor in gastric cancer.

Authors:  Aira Wanajo; Akane Sasaki; Hiromi Nagasaki; Shu Shimada; Takeshi Otsubo; Syuichi Owaki; Yasufumi Shimizu; Yoshinobu Eishi; Kazuyuki Kojima; Yasuaki Nakajima; Tatsuyuki Kawano; Yasuhito Yuasa; Yoshimitsu Akiyama
Journal:  Gastroenterology       Date:  2008-05-16       Impact factor: 22.682

5.  Methylation of protocadherin 10, a novel tumor suppressor, is associated with poor prognosis in patients with gastric cancer.

Authors:  Jun Yu; Yuen Y Cheng; Qian Tao; Kin F Cheung; Cleo N Y Lam; Hua Geng; Lin-Wei Tian; Ying P Wong; Joanna H M Tong; Jian-Ming Ying; Hongchuan Jin; Ka F To; Francis K L Chan; Joseph J Y Sung
Journal:  Gastroenterology       Date:  2008-10-29       Impact factor: 22.682

Review 6.  HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target.

Authors:  C Gravalos; A Jimeno
Journal:  Ann Oncol       Date:  2008-04-25       Impact factor: 32.976

7.  Expression of phosphatase regenerating liver 3 is an independent prognostic indicator for gastric cancer.

Authors:  Ni Dai; Ai-Ping Lu; Cheng-Chao Shou; Ji-You Li
Journal:  World J Gastroenterol       Date:  2009-03-28       Impact factor: 5.742

8.  Frameshift mutations of Wnt pathway genes AXIN2 and TCF7L2 in gastric carcinomas with high microsatellite instability.

Authors:  Min Sung Kim; Sung Soo Kim; Chang Hyeok Ahn; Nam Jin Yoo; Sug Hyung Lee
Journal:  Hum Pathol       Date:  2008-08-27       Impact factor: 3.466

9.  Comparison of the prognostic value of a panel of tissue tumor markers and established clinicopathological factors in patients with gastric cancer.

Authors:  Jan-Patrik Wiksten; Johan Lundin; Stig Nordling; Arto Kokkola; Caj Haglund
Journal:  Anticancer Res       Date:  2008 Jul-Aug       Impact factor: 2.480

10.  MAL promoter hypermethylation as a novel prognostic marker in gastric cancer.

Authors:  T E Buffart; R M Overmeer; R D M Steenbergen; M Tijssen; N C T van Grieken; P J F Snijders; H I Grabsch; C J H van de Velde; B Carvalho; G A Meijer
Journal:  Br J Cancer       Date:  2008-11-11       Impact factor: 7.640

View more
  54 in total

1.  Detection of Gastric Cancer with Novel Methylated DNA Markers: Discovery, Tissue Validation, and Pilot Testing in Plasma.

Authors:  Bradley W Anderson; Yun-Suhk Suh; Boram Choi; Hyuk-Joon Lee; Tracy C Yab; William R Taylor; Brian A Dukek; Calise K Berger; Xiaoming Cao; Patrick H Foote; Mary E Devens; Lisa A Boardman; John B Kisiel; Douglas W Mahoney; Seth W Slettedahl; Hatim T Allawi; Graham P Lidgard; Thomas C Smyrk; Han-Kwang Yang; David A Ahlquist
Journal:  Clin Cancer Res       Date:  2018-05-29       Impact factor: 12.531

2.  Abnormal FHIT protein expression may be correlated with poor prognosis in gastric cancer: a meta-analysis.

Authors:  He-Ling Wang; Ping-Yi Zhou; Peng Liu; Yu Zhang
Journal:  Tumour Biol       Date:  2014-04-12

Review 3.  [Current biomarkers for gastric cancer].

Authors:  G B Baretton; D E Aust
Journal:  Pathologe       Date:  2017-03       Impact factor: 1.011

4.  Long noncoding RNA CCAT1, which could be activated by c-Myc, promotes the progression of gastric carcinoma.

Authors:  Feng Yang; Xuchao Xue; Jianwei Bi; Luming Zheng; Kangkang Zhi; Yan Gu; Guoen Fang
Journal:  J Cancer Res Clin Oncol       Date:  2012-11-11       Impact factor: 4.553

5.  Expression and clinical significance of the microRNA-200 family in gastric cancer.

Authors:  Liang Chang; Fengjie Guo; Bingjie Huo; Yalei Lv; Yudong Wang; Wei Liu
Journal:  Oncol Lett       Date:  2015-03-11       Impact factor: 2.967

6.  Increased expression of DLX2 correlates with advanced stage of gastric adenocarcinoma.

Authors:  Peng Tang; Hua Huang; Jiang Chang; Gong-Fang Zhao; Ming-Liang Lu; Yan Wang
Journal:  World J Gastroenterol       Date:  2013-05-07       Impact factor: 5.742

7.  Ectopic expression of RASSF2 and its prognostic role for gastric adenocarcinoma patients.

Authors:  Deng Luo; Ting Ye; Tian-Qian Li; Peng Tang; Sha-Dong Min; Gong-Fang Zhao; Hua Huang; Jiang Chang; Yan Wang; Lin Lv; Ming-Liang Lu; Meng-Yao Zheng
Journal:  Exp Ther Med       Date:  2011-12-28       Impact factor: 2.447

8.  Microsatellite instability of gastric cancer and precancerous lesions.

Authors:  Bing Li; Hong-Yi Liu; Shao-Hua Guo; Peng Sun; Fang-Ming Gong; Bao-Qing Jia
Journal:  Int J Clin Exp Med       Date:  2015-11-15

Review 9.  Perspectives on new biomarkers in gastric cancer: diagnostic and prognostic applications.

Authors:  Danilo do Rosário Pinheiro; Wallax Augusto Silva Ferreira; Mariceli Baia Leão Barros; Mariana Diniz Araújo; Symara Rodrigues-Antunes; Bárbara do Nascimento Borges
Journal:  World J Gastroenterol       Date:  2014-09-07       Impact factor: 5.742

10.  Tissue Inhibitor of Metalloproteinase-1 Is Confined to Tumor-Associated Myofibroblasts and Is Increased With Progression in Gastric Adenocarcinoma.

Authors:  Warner Alpízar-Alpízar; Ole Didrik Laerum; Ib J Christensen; Kjell Ovrebo; Arne Skarstein; Gunilla Høyer-Hansen; Michael Ploug; Martin Illemann
Journal:  J Histochem Cytochem       Date:  2016-07-01       Impact factor: 2.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.